Table 2.
Treatments received
| Patients (n = 56) | |
|---|---|
| Received before osimertinib | n (%) |
| EGFR‐TKIs | 56 (100) |
| Gefitinib | 38 (67.9) |
| Erlotinib | 28 (50.0) |
| Afatinib | 21 (37.5) |
| EGFR‐TKI rechallenge | 3 (5.4) |
| Cytotoxic agents | 35 (62.5) |
| Platinum combination therapy | 33 (58.9) |
| Anti‐PD‐1 antibody | 1 (1.8) |
| Number of previous regimens (median, range) | 2 (1–14) |
| 1 | 19 (33.9) |
| 2 | 15 (26.8) |
| ≥ 3 | 22 (39.3) |
| Received after osimertinib | Patients (n = 26) |
| Number (%) | |
| Cytotoxic agents | 16 (61.5) |
| EGFR‐TKIs | 11 (42.3) |
| Gefitinib | 4 (15.4) |
| Erlotinib | 6 (23.1) |
| Afatinib | 4 (15.4) |
| Osimertinib | 1 (3.8) |
| Anti‐PD‐1 antibody | 6 (23.1) |
EGFR, epidermal growth factor receptor; PD‐1, programmed death protein‐1; TKI, tyrosine kinase inhibitor.